Bli medlem
Bli medlem

Du är här

2021-04-09

Guard Therapeutics receives an Intention to Grant notice in Europe for ROSgard

Guard Therapeutics AB (publ.) today announces that the company has received an Intention to Grant notice from the European Patent Office (EPO) for a patent application concerning its biological investigational drug ROSgard as a product, including its medical use. The next step in the process is a formal EPO approval, which provides a patent protection until 2037.

The patent application, with application number no. 17711205.9, for which the EPO has issued an Intention to Grant notice, refers to the company’s lead investigational drug ROSgard as a product (“composition of matter”) and its medical use. The notice means that the EPO intends to approve the company’s patent application but that a number of administrative steps remain before a final notice of approval can be issued. The patent, when granted, provides protection of ROSgard in Europe until 2037.
 
In addition to the Intention to Grant in Europe, Guard Therapeutics recently obtained approval of the corresponding patent in the US and Australia. The company has pending patent applications for ROSgard in several other major countries, including Japan, China, Canada and Brazil.
 
“With the EPO Intention to Grant notice in Europe, which follows the recent approval in the US for the corresponding patent, Guard Therapeutics has now obtained important patent protection for ROSgard in a large part of the global pharmaceutical market. We are happy for these successes in our continuous efforts to build value in our patent portfolio”, Tobias Agervald, CEO of Guard Therapeutics says.

For further information, please contact:


Tobias Agervald, CEO
Telephone: +46 46 286 50 30
E-mail: info@guardtherapeutics.com 

About Guard Therapeutics


Guard Therapeutics is a pharmaceutical company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company’s clinical investigational drug ROSgard is being developed as a protective treatment against acute kidney injury with an initial focus on patients undergoing heart surgery. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

Certified Adviser is Svensk Kapitalmarknadsgranskning AB, tel. +46 11 32 30 732, ca@skmg.se.

This information is information that Guard Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-04-09 08:35 CEST.

Attachments


Guard Therapeutics receives an Intention to Grant notice in Europe for ROSgard

Författare MFN

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.